Swiss medicines regulator Swissmedic has approved Coartem Baby, a Novartis anti-malaria drug developed for infants weighing between two and five kilos. +Get the most important news from Switzerland in your inbox This is a significant step in global efforts to improve access to life-saving treatments for vulnerable populations, Swissmedic wrote in a statement today. The product fills a serious treatment gap for one of the most vulnerable patient groups. + Switzerland's global role in fighting malaria The availability of a treatment specifically designed for girls and young children marks an important step forward in the global fight against malaria. The approval process for the product - also known as Riamet Baby in some countries - involved close collaboration with the national regulatory authorities of eight African countries: Burkina Faso, Ivory Coast, Kenya, Malawi, Mozambique, Nigeria, Uganda and Tanzania. The Global Malaria Programme of the World Health Organisation (WHO) also ...
Full story here
Are you the author?
SWI swissinfo.ch – the international service of the Swiss Broadcasting Corporation (SBC).
Since 1999, swissinfo.ch has fulfilled the federal government’s mandate to distribute information about Switzerland internationally, supplementing the online offerings of the radio and television stations of the SBC. Today, the international service is directed above all at an international audience interested in Switzerland, as well as at Swiss citizens living abroad.
Previous post
See more for 3.) Swissinfo Business and Economy
Next post
Tags:
Featured,
newsletter
